US Stock MarketDetailed Quotes

LRMR Larimar Therapeutics

Watchlist
  • 3.340
  • +0.070+2.14%
Close Feb 14 16:00 ET
  • 3.350
  • +0.010+0.30%
Post 20:01 ET
213.11MMarket Cap-2.90P/E (TTM)

About Larimar Therapeutics Company

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Company Profile

SymbolLRMR
Company NameLarimar Therapeutics
Listing DateJun 19, 2014
Issue Price16.00
Founded2005
CEODr. Carole Ben-Maimon, M.D.
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address3 Bala Plaza East,Suite 506
CityBala Cynwyd
ProvincePennsylvania
CountryUnited States of America
Zip Code19004
Phone1-844-511-9056
Websitehttp://larimartx.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Carole Ben-Maimon, M.D.
  • Director, President and Chief Executive Officer
  • 3.14M
  • Dr. Gopi Shankar, F.A.A.P.,M.B.A.,PhD
  • Chief Development Officer
  • 1.38M
  • Dr. Russell G. Clayton, D.O.
  • Chief Medical Officer
  • --
  • Michael Celano
  • Chief Financial Officer and Principal Accounting Officer
  • 1.42M
  • Joseph Truitt
  • Chairman of the Board
  • 114.96K
  • Thomas Edward Hamilton
  • Independent Director
  • 77.77K
  • Dr. Jeffrey W. Sherman, F.A.C.P.,M.D.
  • Independent Director
  • 56.43K
  • Frank E. Thomas
  • Independent Director
  • 86.21K
  • Jonathan S. Leff
  • Independent Director
  • 79.96K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
HENDERA
831152
+30.00%
Hengerda New Materials
300946
+20.01%
Fujian Nebula Electronics.,Ltd
300648
+20.00%
4
HNAC Technology
300490
+19.95%
5
Cubic Digital Technology
300344
+18.30%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More
FOMC Press Conference, January 29, 2025